Neurizon Therapeutics (ASX:NUZ) will begin "in the coming weeks" the two pharmacokinetic studies that are necessary to lift the clinical suspension on its investigational new drug application for NUZ-001, according to a Monday filing with the Australian bourse.
The US Food and Drug Administration placed the application for NUZ-001 under clinical hold last January amid concerns about the adequacy of relevant information, raising potential risks to human subjects.
Neurizon said the two upcoming pharmacokinetic studies will provide additional animal exposure data specifically requested by the US FDA to assess the adequacy of systemic exposure to NUZ-001. A formal response from the regulator is expected within the next 60 days, the filing stated.
Neurizon expects the studies to cost between AU$400,000 and AU$600,000, which is eligible for a government R&D rebate, per the filing.
The biotechnology company is developing NUZ-001 for the treatment of amyotrophic lateral sclerosis or ALS, which is the most common form of motor neuron disease.
Neurizon's shares fell 5% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。